Oncology
Refine Search
Pharmaceutical
French biotech start-up studio Argobio and non-profit biomedical research center the Institut Pasteur have announced the launch of Enodia Therapeutics. 26 February 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review Regeneron Pharmaceuticals’ resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. 26 February 2025
Biotechnology
California-based biotech Eikon Therapeutics today announced the initial closing of a $350.7 million Series D financing. Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses, the company noted. 26 February 2025
Biotechnology
Repare Therapeutics is set to cut approximately 75% of its workforce as part of a restructuring plan aimed at extending its cash reserves into mid-2027. 26 February 2025
Pharmaceutical
Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically-significant and clinically-meaningful improvement in the primary endpoint of progression-free survival (PFS). 26 February 2025
Biotechnology
Ryvu Therapeutics saw its shares tumble nearly 13% to 22.70 zloty by close of trading today, as the Polish oncology-focused biotech company announced a strategic reorganization that will extend Ryvu’s cash runway to second-half 2026 to focus on driving the RVU120 clinical program and the early pipeline to key data inflection points. 25 February 2025
Biotechnology
UK-based Swarm Oncology, a biotech developing T-cell therapies to achieve long-term remission in advanced solid cancers, has announced a strategic partnership with cell and gene therapy-focused contract development and manufacturing organization Cellex Cell Professionals. 25 February 2025
Biotechnology
Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial collaboration with Pfizer to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of the US pharma giant’s antibody drug conjugates (ADCs) across multiple solid tumor settings. 25 February 2025
Biotechnology
The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ Phase III study. 25 February 2025
Pharmaceutical
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. 24 February 2025
Pharmaceutical
Earlier this month, the Norwegian government launched the cancer strategy Joint Efforts Against Cancer, with five national goals and 17 new ten-year goals, which set ambitions for the cancer area up to 2035. 24 February 2025
Pharmaceutical
India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a rising cancer burden and demand for cutting-edge treatments. Leading the charge are big domestic pharma spearheading the launch of breakthrough oncology drugs. 23 February 2025
Pharmaceutical
Privately-held Austria firm pharmaand GmbH (pharma&) today announced that the National Institute of Health and Care Excellence (NICE) has issued a positive recommendation for its Rubraca (rucaparib). 21 February 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending the use Breyanzi (lisocabtagene maraleucel) for National Health Service (NHS) in England. 21 February 2025
Biosimilars
South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars. 20 February 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody Tecentriq intravenous infusion (atezolizumab) for an additional indication of unresectable alveolar soft part sarcoma. 20 February 2025
Biotechnology
CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma for the development and commercialization of SYS6005, a recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate (ADC). 20 February 2025
Biotechnology
February 20, 2025
New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an interleukin-12 (IL-12) DNA-based immunotherapy in development for the treatment of newly diagnosed advanced ovarian cancer. The firm’s shares edged up 3.3% to $0.90 on the news, although they fell back by close of trading 20 February 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to Dutch clinical-stage drug developer Merus for its petosemtamab. 19 February 2025
Biotechnology
Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and pipeline advancement. 19 February 2025
Biotechnology
China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines, handing over rights to multiple fully human antibodies discovered through its proprietary RenMice platform. 10 July 2025
Biotechnology
US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. 10 July 2025
Biotechnology
The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025
Biotechnology
US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases. 10 July 2025
Biotechnology
BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene - has announced that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment. 10 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted the supplemental new drug application (sNDA) for Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy. 10 July 2025
Biotechnology
Radiant Biotherapeutics, a Canadian biotech advancing multi-specific, multi-affinity antibody (Multabody) therapeutics in cancer and autoimmune diseases, has announced the appointment of Deborah Geraghty as president and chief executive. 9 July 2025
Pharmaceutical
New Jersey, USA-headquartered Champions Oncology, a translational oncology research organization, yesterday announced the full commercial launch of its radiopharmaceutical services platform. 9 July 2025
Biotechnology
US oncology-focused biotech Crescent Biopharma has appointed Jan Pinkas as chief scientific officer (CSO). 8 July 2025
Biosimilars
The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing US biotech major Amgen’s (Nasdaq: AMGN) denosumab brands Prolia and Xgeva, had been launched in the USA. 8 July 2025
Biotechnology
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
Biotechnology
French biotech Nanobiotix’ shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica, a Johnson & Johnson subsidiary. 8 July 2025
Biotechnology
The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple myeloma, according to a report on the field by DelveInsight. 7 July 2025
Biosimilars
Indian biosimilars company Biocon Biologics, a subsidiary of Biocon, today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorizations for Vevzuo and Evfraxy, biosimilars of Amgen’s (Nasdaq: AMGN) denosumab (trade names Xgeva and Prolia). 7 July 2025
Pharmaceutical
A Dutch appeals court has ruled that health insurers acted unlawfully in their group tender for three CDK 4/6 inhibitors, reigniting debate over cost-driven drug policies in the Netherlands. The case centered on whether insurers can restrict prescribing choices for innovative cancer drugs that differ in clinical profiles. 7 July 2025
Biotechnology
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate CPTX2309, for up to $2.1 billion. Organon posted disappointing mid-stage trial results for its investigational endometriosis pain drug, OG-6219. Also of note last week, the US Food and drug Administration (FDA) granted accelerated approval for Regeneron’s multiple myeloma drug Lynozyfic. 6 July 2025
Pharmaceutical
Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a privately-held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. 4 July 2025
Biosimilars
Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for Vevzuo and Evfraxy biosimilars of denosumab, originated by Amgen. 4 July 2025
Biotechnology
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter. 4 July 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze